| Dr Angel Demetress Leake, MD | |
|
500 E 51st St, Division Of Infectious Diseases--rm 7007, Chicago, IL 60615-2400 | |
| (312) 572-2363 | |
| Not Available |
| Full Name | Dr Angel Demetress Leake |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Infectious Disease |
| Location | 500 E 51st St, Chicago, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679729842 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 036113650 (Illinois) | Primary |
| Entity Name | Cook County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588612832 PECOS PAC ID: 2860398088 Enrollment ID: O20031209000747 |
News Archive
People with egg or gelatin allergies shouldn't assume that just because they've had a flu shot safely in the past they will be able to again, according to a new study, presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16.
A new study this week reveals that the mental health problems among young adults and adolescents is on the rise. Over the last few years there has been a steep rise in episodes of depression and psychological distress among the younger population says the study.
Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.
The hypocretin/orexin (HCRT) system of the brain is best known for promoting wakefulness and appetite. A new paper in Biological Psychiatry suggests that blocking hypocretin signaling via the HCRT-1 receptor (HCRT-R1) might also reduce the appetite for cocaine.
Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.
› Verified 1 days ago
| Entity Name | Christian Community Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790888238 PECOS PAC ID: 4284533183 Enrollment ID: O20040108000515 |
News Archive
People with egg or gelatin allergies shouldn't assume that just because they've had a flu shot safely in the past they will be able to again, according to a new study, presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16.
A new study this week reveals that the mental health problems among young adults and adolescents is on the rise. Over the last few years there has been a steep rise in episodes of depression and psychological distress among the younger population says the study.
Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.
The hypocretin/orexin (HCRT) system of the brain is best known for promoting wakefulness and appetite. A new paper in Biological Psychiatry suggests that blocking hypocretin signaling via the HCRT-1 receptor (HCRT-R1) might also reduce the appetite for cocaine.
Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Angel Demetress Leake, MD 500 E 51st St, Division Of Infectious Diseases--rm 7007, Chicago, IL 60615-2400 Ph: (312) 572-2363 | Dr Angel Demetress Leake, MD 500 E 51st St, Division Of Infectious Diseases--rm 7007, Chicago, IL 60615-2400 Ph: (312) 572-2363 |
News Archive
People with egg or gelatin allergies shouldn't assume that just because they've had a flu shot safely in the past they will be able to again, according to a new study, presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16.
A new study this week reveals that the mental health problems among young adults and adolescents is on the rise. Over the last few years there has been a steep rise in episodes of depression and psychological distress among the younger population says the study.
Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.
The hypocretin/orexin (HCRT) system of the brain is best known for promoting wakefulness and appetite. A new paper in Biological Psychiatry suggests that blocking hypocretin signaling via the HCRT-1 receptor (HCRT-R1) might also reduce the appetite for cocaine.
Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.
› Verified 1 days ago
Dr. Sorin C Danciu, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3134 N Clark St, Chicago, IL 60657 Phone: 773-880-9722 | |
Anoopa A. Koshy, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 259 E Erie St Ste 2200, Chicago, IL 60611 Phone: 312-926-6000 | |
William Edmond Gerardi, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 3730 N Lake Shore Dr, Apartment 2a, Chicago, IL 60613 Phone: 773-244-3060 | |
Suparna Dutta, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1700 W Van Buren St, Suite 500, Chicago, IL 60612 Phone: 312-942-4200 Fax: 312-942-3568 | |
Alexandra Dumitrescu, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5841 S Maryland Ave, Chicago, IL 60637 Phone: 888-824-0200 | |
Dr. Mitesh Mahesh Kabadi, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St Ste 1159, Chicago, IL 60612 Phone: 312-942-5020 | |
Dr. Marta Batus, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St, Suite 809, Chicago, IL 60612 Phone: 312-563-2487 Fax: 312-942-3192 |